12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tcelna: Phase IIb started

Opexa began the double-blind, placebo-controlled, North American Phase IIb Abili-T trial to evaluate Tcelna in about 180 patients with evidence of disease progression without associated relapses. Patients will receive 5 subcutaneous injections of Tcelna administered...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >